Enbrel ex-McKinsey nerd





































With fresh $160M, RayzeBio plots sprint through the clinic for lead radiopharmaceutical program — building on Novartis' success

Ever since its launch in 2020, backed by Versant and venBio, RayzeBio has talked at length about building a platform company to fulfill the potential that radiopharmaceuticals hold — with seven active programs to boast. But it’s stayed mum about what those programs actually are, instead sticking to updates about new funding, hires or partnerships.

That’s by design, according to CEO Ken Song. The former Venrock VC and serial biotech entrepreneur wanted to make sure that he had a real business case before becoming more visible.


I am sure he is jealous of former McKinsey colleague and friend who is far more successful than him while he toils in mediocrity at Amgen. This isn't even including his younger brother Kyle who is at elite venture capital firm Flagship Pioneering that started Moderna.
 






I am sure he is jealous of former McKinsey colleague and friend who is far more successful than him while he toils in mediocrity at Amgen. This isn't even including his younger brother Kyle who is at elite venture capital firm Flagship Pioneering that started Moderna.

let it go already, bro man. You are better than this. Surely you have your own life to live instead of obsessing over Jay for five years
 








































































McKinsey advice is why Enbrel keeps raising the price. I heard McKinsey is top notch in developing heartless, mean spirited Aholes well.

list-price-increases.jpg